A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Completed · Phase 3 · NCT04026412
Conditions: Non-Small Cell Lung Cancer (NSCLC)
At a glance
- Research payments reported, 2025
- $935
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 925
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- nivolumab (biological), ipilimumab (biological), durvalumab (biological)
- Dates
- Started 2019-10-08; completion 2024-11-26
- Results posted
- Yes
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
From ClinicalTrials.gov, last updated 2025-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $935 in research payments for this study in 2025 (1 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Onco Southwest Fort Worth $935
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.